Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel injection aims to smooth out acne scars

NCT ID NCT07207369

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an injectable gel called ELAPR002f to see if it safely reduces atrophic acne scars (indented scars) on the cheeks. About 395 adults with moderate to severe scarring will receive either the gel or a saline placebo over 2 months, then be followed for a year. The goal is to measure scar improvement and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 395 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants in general good health, and seeking improvement of atrophic acne scars. * Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale \[ASIS\]) on each cheek based on evaluating investigator (EI) live assessment (both cheeks must qualify but do not need to have the same score) at the first Screening Visit. * At least 5 rolling or boxcar-type acne scars in total within the predefined 4 cm × 4 cm assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator (TI). Exclusion Criteria: * The participant has clinically significant acne on the face. * Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face. * The participant presents with predominantly ice pick scars. * History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation or hypopigmentation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne scars are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne scars

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Research Associates - Glendale /ID# 254961

    RECRUITING

    Glendale, Arizona, 85308, United States

  • Aesthetic Center at Woodholme /ID# 256197

    RECRUITING

    Baltimore, Maryland, 21208-6391, United States

  • Austin Institute for Clinical Research - Pflugerville /ID# 256200

    RECRUITING

    Pflugerville, Texas, 78660, United States

  • DMR Research PLLC /ID# 256199

    RECRUITING

    Westport, Connecticut, 06880, United States

  • Hamilton Research, LLC /ID# 256925

    RECRUITING

    Alpharetta, Georgia, 30022, United States

  • Marcus Facial Plastic Surgery /ID# 275880

    RECRUITING

    Redondo Beach, California, 90277, United States

  • Pacific Clinical Innovations /ID# 256185

    RECRUITING

    Vista, California, 92083-6030, United States

  • SkinDC /ID# 254962

    RECRUITING

    Arlington, Virginia, 22209, United States

  • The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182

    RECRUITING

    Mount Kisco, New York, 10549-3028, United States

  • Wilmington Dermatology Center /ID# 256192

    RECRUITING

    Wilmington, North Carolina, 28403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.